|Articles|February 8, 2012

Pfizer Proactive in Birth Control Pill Recall

HCLBlog

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: FDA Approves Datroway

ByNicholas Jacobus

May 22nd 2026

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

ByNicholas Jacobus

May 22nd 2026

Director of NIH Infectious Disease Institute Steps Down

ByMike Hollan

May 22nd 2026

The Biotech Industry’s Relationship with Real-Time Data: Q&A with Dr. Richard Graham

ByMike Hollan,Dr. Richard Graham

May 22nd 2026

Modern Communication Between FDA, Biotech, and Investors: Q&A with David Crean

ByMike Hollan,David Crean

May 22nd 2026

Pfizer Proactive in Birth Control Pill Recall

Related Content

Pharmaceutical Executive Daily: FDA Approves Datroway

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Director of NIH Infectious Disease Institute Steps Down

The Biotech Industry’s Relationship with Real-Time Data: Q&A with Dr. Richard Graham

Modern Communication Between FDA, Biotech, and Investors: Q&A with David Crean

Trending on PharmExec

Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report

The Evolving Relationship Between FDA and Biotech

Pharmaceutical Executive Daily: FDA Approves Datroway